Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study. - Wikidata - awgldk - TriplyDB

Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.

Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.

http://www.wikidata.org/entity/Q37530604

about

Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.

http://www.wikidata.org/entity/Q37530604

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@en

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@nl

type

label

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@en

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@nl

prefLabel

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@en

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@nl

P1433

Q37530604-300854B1-3E98-4874-BBD4-E568B67AEDDF

P1476

Q37530604-8375308F-ABA7-4E10-A917-D0F9A080088E

P2093

Q37530604-188EDFE9-71FF-47E0-B38A-E4EF99F2275F

Q37530604-277D7034-FBA0-4C40-B001-58E6AD198B4F

Q37530604-3AE44363-DDAE-49D4-9AF4-20E72FFE9C33

Q37530604-7664997A-9407-41F6-9FDB-AE3305889720

Q37530604-D2C650FE-859A-4E45-8476-E02E761D0CD5

Q37530604-DF7995D5-705E-4251-8B4F-C27C071B95D4

P2860

Q37530604-0AE41588-EEA9-4074-ACE8-3E434C7B96F9

Q37530604-0FA622AA-0643-4460-A0D4-1E3F7DDC4B65

Q37530604-114F4CA9-D0BD-488B-ADA4-6B35CC150782

Q37530604-19C9A104-FC36-44BE-85DD-71DBAF7264D8

Q37530604-26FC990B-73FC-4BF3-80B1-A89158145659

Q37530604-2ED28636-4097-4AA5-83BB-9A30F7466FCC

Q37530604-303A4F3E-381C-4261-8BA7-2A7CFC11B266

Q37530604-30E1EDA1-B0F4-455A-9C79-3254DD1976D8

Q37530604-37D4C055-D3B1-4178-9A0E-F7B6B1E41F95

Q37530604-3F07BD36-6752-4C4C-B584-BA694D14D3CC

P304

Q37530604-961966AB-C2FB-444B-9D37-9998C7FB8B89

P31

Q37530604-96C6C7B4-75F5-46CB-8762-76C9F5352463

P356

Q37530604-B5B39FE3-83C8-46A9-BB23-F7D70A01664E

P407

Q37530604-BCBCE0AC-24F0-48FF-A741-09AFC466186B

P433

Q37530604-2735F92D-CB36-4418-9DF4-FE2757E23747

P478

Q37530604-5AE2B820-429E-4FC7-B085-4CBEEDD7F36F

P577

Q37530604-3BB3C94F-4235-45B4-B79B-B6CAA23AC0C7

P698

Q37530604-FFD68888-9064-4498-B711-855D977E376B

P921

Q37530604-B5518C18-BD9C-47D5-A07A-6C0A412DA671

P932

Q37530604-4E6B4E9B-0552-4904-BDDC-ED9F8CBDF3D5

P356

MD.0000000000005696

P1433

P1476

Effects of sequential paclitax ...... ctive, STROBE-compliant study.

@en

P2093

Fei Wang

http://www.w3.org/2001/XMLSchema#string

Hao Yu

http://www.w3.org/2001/XMLSchema#string

Naifu Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoxia Li

http://www.w3.org/2001/XMLSchema#string

Xiugui Sheng

http://www.w3.org/2001/XMLSchema#string

Xuelian Du

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2016

Reporting results of cancer treatment

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.

Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.

P304

e5696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000005696

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28002342

http://www.w3.org/2001/XMLSchema#string

P921

P932

5181826

http://www.w3.org/2001/XMLSchema#string